US 11,752,086 B2
Topical formulations and methods
Lars Erik Peters, Falmouth, ME (US)
Assigned to MYOCEPT INC., Novato, CA (US)
Appl. No. 16/484,430
Filed by MYOCEPT INC., Novato, CA (US)
PCT Filed Feb. 7, 2018, PCT No. PCT/US2018/017301
§ 371(c)(1), (2) Date Aug. 7, 2019,
PCT Pub. No. WO2018/148338, PCT Pub. Date Aug. 16, 2018.
Claims priority of provisional application 62/456,066, filed on Feb. 7, 2017.
Prior Publication US 2020/0009040 A1, Jan. 9, 2020
Int. Cl. A61K 8/81 (2006.01); A61K 8/06 (2006.01); A61K 8/64 (2006.01); A61K 8/73 (2006.01); A61K 9/00 (2006.01); A61K 9/107 (2006.01); A61K 31/728 (2006.01); A61K 38/08 (2019.01); A61K 38/17 (2006.01); A61K 38/28 (2006.01); A61K 45/06 (2006.01); A61K 47/32 (2006.01); A61K 47/58 (2017.01); A61P 17/00 (2006.01); A61P 17/18 (2006.01); A61Q 19/00 (2006.01); A61Q 19/08 (2006.01)
CPC A61K 8/8158 (2013.01) [A61K 8/068 (2013.01); A61K 8/64 (2013.01); A61K 8/735 (2013.01); A61K 9/0014 (2013.01); A61K 9/1075 (2013.01); A61K 31/728 (2013.01); A61K 38/08 (2013.01); A61K 38/1703 (2013.01); A61K 38/1709 (2013.01); A61K 38/28 (2013.01); A61K 45/06 (2013.01); A61K 47/32 (2013.01); A61K 47/58 (2017.08); A61P 17/00 (2018.01); A61P 17/18 (2018.01); A61Q 19/00 (2013.01); A61Q 19/08 (2013.01)] 15 Claims
 
1. A topical formulation for dermal delivery comprising an amphipol polymer ionically paired with at least one charged bioactive agent in a dermatologically acceptable vehicle, wherein said dermatologically acceptable vehicle is a water-in-oil or oil-in-water nanoemulsion, and said at least one charged bioactive agent is a selected from the group consisting of neurotoxins, antibodies and insulin, and said amphipol polymer is selected from the group consisting of A8-35 and PMAL.
 
5. A topical formulation for dermal or transdermal delivery comprising an amphipol polymer ionically paired with at least one charged bioactive agent, together with at least one TJ-modulating peptide in a dermatologically acceptable vehicle, wherein said dermatologically acceptable vehicle is a water-in-oil or oil-in-water nanoemulsion, and wherein said at least one charged bioactive agent is selected from the group consisting of neurotoxins, antibodies and insulin or peptide and said amphipol polymer is selected from the group consisting of A8-35 and PMAL.